Brief: Can-Fite Announces Positive Top-Line Results From Piclidenoson Phase Iii Comfort Study In Moderate To Severe Psoriasis
29/06/2022 12:03
June 29 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE ANNOUNCES POSITIVE TOP-LINE RESULTS FROM
PICLIDENOSON
PHASE III COMFORT™ STUDY IN MODERATE TO SEVERE PSORIASIS
* CAN FITE BIOPHARMA - PHASE III STUDY MET PRIMARY ENDPOINT
WITH
STATISTICALLY SIGNIFICANT IMPROVEMENT, PICLIDENOSON HAD
EXCELLENT SAFETY PROFILE
* CAN FITE BIOPHARMA LTD - CAN-FITE HAS LICENSING DEALS FOR
MARKETING OF PICLIDENOSON FOR TREATMENT OF PSORIASIS IN MULTIPLE
GLOBAL REGIONS
Source text for Eikon: ID:nBw8s5F8a
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage